Key Highlights ARK Invest purchased 51,477 Meta Platforms shares totaling approximately $38 million across three exchange-traded funds Meta’s stock price jumped roughly 11.5% Monday, fueled b
On Monday, September 21, 2026, Cathie Wood’s ARK Invest executed two divergent portfolio adjustments. The investment firm significantly increased its Meta Platforms holdings while simultaneously reducing its CrowdStrike position, despite both securities experiencing upward price movement.
Meta experienced an impressive surge of approximately 11.5% during Monday’s trading session. This dramatic price appreciation was largely attributed to heightened market interest in Muse, Meta’s newly unveiled personal AI agent. The application quickly ascended to the number-one position on Apple’s U.S. free-app rankings, indicating strong early adoption among consumers.
Muse represents a significant departure from conventional chatbot technology. The AI agent possesses capabilities including sending emails, arranging travel accommodations, completing digital forms, and executing online transactions autonomously on users’ behalf.
ARK accumulated 51,477 shares of Meta distributed across its ARKK, ARKW, and ARKF exchange-traded funds. The combined acquisition represented approximately $38 million in investment value.
The upcoming Meta Connect conference, set for September 23-24, presents an opportunity for CEO Mark Zuckerberg to elaborate on emerging AI offerings and wearable technology initiatives. The event may provide investors with deeper insights into Muse’s development roadmap and Meta’s comprehensive artificial intelligence strategy.
Analyst sentiment toward Meta remains overwhelmingly favorable. The stock commands a Strong Buy consensus rating from 44 Wall Street analysts, comprising 38 Buy recommendations and 6 Hold ratings. The consensus price target stands at $763.67, suggesting approximately 3% appreciation potential from present trading levels.
CrowdStrike shares advanced nearly 5% during Monday’s session. Cybersecurity equities received upward momentum from market expectations that proliferating AI agents will create expanded attack surfaces requiring enhanced digital security measures.
Notwithstanding this price appreciation, ARK divested 28,403 shares of CrowdStrike through its ARKW and ARKF funds. The transaction represented approximately $7 million in proceeds.
CrowdStrike recently conducted its Fal.Con industry conference. During the event, company leadership unveiled innovative solutions designed for the AI agent landscape, including an Agentic Identity Provider and specialized products targeting AI workload protection.
The cybersecurity provider has demonstrated exceptional performance throughout 2026. Shares have appreciated approximately 113% year-to-date. The company reported 25% growth in annual recurring revenue, reaching $5.84 billion in its most recent quarter, while net new ARR surged 51% to achieve a record $333 million.
CrowdStrike maintains a Strong Buy consensus among Wall Street analysts, supported by 31 Buy ratings and 7 Hold ratings. The average price target of $247.10 represents a slight discount to Monday’s closing price of $249.35.
Beyond these prominent portfolio adjustments, ARK expanded positions across multiple biotechnology companies. The firm acquired 102,565 Beam Therapeutics shares, 100,241 Ionis Pharmaceuticals shares, and 74,878 Veracyte shares through its ARKG ETF.
ARK additionally purchased 29,587 Airbnb shares via its ARKW ETF, representing approximately $4.9 million in transaction value.
Regarding portfolio reductions, ARK liquidated positions in Everpure and 10x Genomics, while also selling a modest quantity of ARK 21Shares Bitcoin ETF shares.
ARK further accumulated 61,858 Scribe Therapeutics shares, demonstrating sustained conviction in gene-editing technological advancements.
The post ARK Invest Pours $38M Into Meta (META) While Offloading CrowdStrike (CRWD) Stock appeared first on Blockonomi.
